Abstract
Receptor-targeting peptides have been extensively pursued for improving binding specificity and effective accumulation of drugs at the site of interest, and have remained challenging for extensive research efforts relating to chemotherapy in cancer treatments. By chemically linking a ligand of interest to drug-loaded nanocarriers, active targeting systems could be constructed. Peptide-functionalized nanostructures have been extensively pursued for biomedical applications, including drug delivery, biological imaging, liquid biopsy, and targeted therapies, and widely recognized as candidates of novel therapeutics due to their high specificity, well biocompatibility, and easy availability. We will endeavor to review a variety of strategies that have been demonstrated for improving receptor-specificity of the drug-loaded nanoscale structures using peptide ligands targeting tumor-related receptors. The effort could illustrate that the synergism of nano-sized structures with receptor-targeting peptides could lead to enrichment of biofunctions of nanostructures.
Introduction: Overcoming the Delivery Dilemma
Traditional chemotherapy and small-molecule drugs face a significant "delivery dilemma," often distributing non-specifically throughout the body. This leads to low accumulation at tumor sites and high toxicity in healthy tissues. While nanotechnology initially relied on the Enhanced Permeability and Retention (EPR) effect—a passive targeting mechanism due to leaky tumor vessels—this effect is inconsistent across different patients and tumor types.
Peptides (<10 kDa) offer a "Goldilocks" solution for active targeting: they are small enough for deep tissue penetration, possess low immunogenicity, and are relatively easy to synthesize. However, free peptides are rapidly degraded in the bloodstream. Conjugating these peptides to nanostructures creates a synergistic system that protects the peptide while providing the nanocarrier with high-precision targeting capabilities.
Methodology: Conjugation Strategies and Nanostructure Platforms
The construction of these delivery systems involves two primary considerations: the conjugation strategy and the choice of nanostructure platform.
Conjugation Strategies
- Covalent Attachment: Utilizes stable bonds like maleimide-thiol or EDC/NHS coupling for precise control over peptide orientation.
- Non-covalent Interactions: Leverages electrostatic forces, hydrophobic stacking, or high-affinity pairs like biotin-streptavidin.
- Encapsulation: Peptides are incorporated directly during the synthesis of the nanoparticle precursors.
Nanostructure Platforms
Commonly used platforms include liposomes (lipid bilayers), polymeric micelles (ideal for hydrophobic drugs), gold nanoparticles (AuNPs) for imaging and photothermal therapy, and exosomes, which can cross the blood-brain barrier (BBB). Researchers often utilize the MimoDB database to identify high-affinity peptides via phage display for these platforms.
Key Insights: Multivalency and the Density Dilemma
A major advantage of nanoparticles is their large surface area, allowing for multivalency. Attaching multiple peptide copies to a single carrier achieves much higher binding affinity (avidity) than a single peptide alone. However, ligand density is a critical factor that requires careful optimization.
As shown in Figure 5, increasing peptide density does not always yield better results. High density can lead to faster immune clearance. Studies indicate that a specific density (e.g., 0.25 mol% for certain liposomes) often represents the "sweet spot" for balancing circulation time and targeting efficiency. Additionally, the formation of a "protein corona" in vivo can mask targeting ligands, necessitating peptide designs that regulate this protein layer.
Results and Clinical Success
Peptide-functionalized systems have demonstrated significant therapeutic potential:
- Enhanced Delivery: Peptide-modified micelles have shown a ~3-fold increase in intracellular doxorubicin delivery compared to unmodified versions.
- Crossing Biological Barriers: RVG-peptide modified exosomes successfully delivered siRNA across the BBB to treat neurological conditions in mice.
- Clinical Milestones: Peptide-drug conjugates (PDCs) such as Lutathera and Melflufen have received FDA approval, signaling a clear path forward for more complex nano-formulations.
Conclusion and Future Perspectives
While promising, several hurdles remain for clinical translation. The inconsistency of the EPR effect in humans and the complexity of large-scale manufacturing are major challenges. Future research is shifting toward "smart" or triggered-release systems and "ecological therapy," which aims to regulate the tumor microenvironment rather than just killing individual cells. Improving characterization methods for these particles in complex biological environments will be essential for moving these technologies from the lab to the clinic.
Summary updated